Defining the Most Informative Intermediate Clinical Endpoints for Patients Treated with Salvage Radiotherapy for Prostate-specific Antigen Rise After Radical Prostatectomy
Alberto Martini(The University of Texas MD Anderson Cancer Center), Alberto Briganti(University College London Hospitals NHS Foundation Trust), Thomas Wiegel(University Hospital Ulm), Daniele Robesti(Vita-Salute San Raffaele University), C. Cozzarini(IRCCS Ospedale San Raffaele), Giorgio Gandaglia(Vita-Salute San Raffaele University), Dirk Böhmer(Humboldt-Universität zu Berlin), B. Noris Chiorda(IRCCS Ospedale San Raffaele), Charlien Berghen(KU Leuven), Gert De Meerleer(KU Leuven), Valérie Fonteyne(Ghent University Hospital), Luca Boeri(Ospedale Maggiore), Antonino Battaglia(KU Leuven), Detlef Bartkowiak(University Hospital Ulm), Francesco Montorsi(Vita-Salute San Raffaele University), R. Jeffrey Karnes(Mayo Clinic), Stephen A. Boorjian(Mayo Clinic), Nicola Fossati(Ospedale regionale di Lugano), Shahrokh F. Shariat(Universitätszahnklinik Wien), Piet Ost(Ghent University Hospital), Alberto Bossi(Institut Gustave Roussy), Steven Joniau, Gregor Goldner(Medical University of Vienna), N. Di Muzio(IRCCS Ospedale San Raffaele)
Cited by 4
Related Papers
Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation
|The Lancet Oncology|2020|1.1k
Gender and Bladder Cancer: A Collaborative Review of Etiology, Biology, and Outcomes
|European Urology|2015|688
European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2023 Guidelines
|European Urology|2023|656